Skip to navigation Skip to content

CD30 positive systemic anaplastic large cell lymphoma program in Pharmaceutical Benefits Scheme (PBS) 012-18051139

Expand/Collapse all sectionsExpand all



This document outlines details of PBS-subsidised brentuximab vedotin for patients with CD30 positive systemic anaplastic large cell lymphoma (sALCL).

For details on how to process a PBS Authority, see Processing Complex Authority Required Listings.

CD30 positive systemic anaplastic large cell lymphoma quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB123 form

Written

Electronic

S100:

brentuximab vedotin

No

OPA

Not specified

Yes

Continuing

Telephone

Electronic

S100:

brentuximab vedotin

No

OPA

Not specified

Yes